A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Patrick A. Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Nina Bhardwaj, Kim Margolin, Mark M. Awad, Matthew D. Hellmann, Jessica J. Lin, Terence Friedlander, Meghan E. Bushway, Kristen N. Balogh, Tracey E. Sciuto, Victoria Kohler, Samantha J. Turnbull, Rana Besada, Riley R. Curran, Benjamin Trapp, Julian SchererAsaf Poran, Dewi Harjanto, Dominik Barthelme, Ying Sonia Ting, Jesse Z. Dong, Yvonne Ware, Yuting Huang, Zhengping Huang, Amy Wanamaker, Lisa D. Cleary, Melissa A. Moles, Kelledy Manson, Joel Greshock, Zakaria S. Khondker, Ed Fritsch, Michael S. Rooney, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan

Research output: Contribution to journalArticlepeer-review

162 Scopus citations

Abstract

In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.

Original languageEnglish
Pages (from-to)347-362.e24
JournalCell
Volume183
Issue number2
DOIs
StatePublished - Oct 15 2020

Keywords

  • NEO-PV-01
  • T cell
  • anti-PD-1
  • cancer vaccine
  • checkpoint inhibitor
  • epitope spread
  • immunotherapy
  • metastatic cancer
  • neoantigen
  • personalized vaccine

Fingerprint

Dive into the research topics of 'A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer'. Together they form a unique fingerprint.

Cite this